Cambridge, United Kingdom

Dominik Spensberger

USPTO Granted Patents = 11 

 

Average Co-Inventor Count = 6.8

ph-index = 9

Forward Citations = 206(Granted Patents)


Company Filing History:


Years Active: 2016-2022

Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: Dominik Spensberger: Innovator in Therapeutic Molecules

Introduction

Dominik Spensberger is a prominent inventor based in Cambridge, GB. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic molecules. With a total of 11 patents to his name, Spensberger is recognized for his innovative approaches to medical science.

Latest Patents

One of his latest patents focuses on animal models and therapeutic molecules. This invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains. It includes antibodies and antibody chains produced through these methods, as well as derivatives such as fully humanized antibodies. The patent also covers compositions comprising these antibodies, antibody chains, and derivatives, along with cells, non-human mammals, and vectors suitable for use in the described methods.

Career Highlights

Spensberger is currently associated with Kymab Limited, a company known for its cutting-edge research in immunology and therapeutic development. His work at Kymab has positioned him as a key player in the advancement of antibody technology.

Collaborations

Throughout his career, Spensberger has collaborated with notable professionals in the field, including Allan Bradley and E-Chiang Lee. These collaborations have further enhanced his research and innovation capabilities.

Conclusion

Dominik Spensberger's contributions to the field of therapeutic molecules and his innovative patents underscore his importance as an inventor. His work continues to influence advancements in biotechnology and medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…